Special Issue

Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development

Message from the Guest Editor

Neutralizing antibodies are important indicators for the evaluation of the effectiveness of SARS-CoV-2 vaccines. At present, there are many methods for detecting SARS-CoV-2 neutralizing antibodies, including culture live virus neutralization method, recombinant replication virus neutralization method, pseudotyped virus neutralization method, and competition inhibition neutralization antibody detection method. Even if the same type of method is used, specific operations in different laboratories can lead to differences in results. As a result, the neutralizing antibody test results of different vaccines are incomparable, meaning that the immunogenicity of different vaccines cannot be compared horizontally. In this Special Issue, original research articles and reviews are welcome, include (but are not limited to) the following: (i) recent advances in novel neutralization assay development, (ii) standardization and comparison of different SARS-CoV-2 neutralization assays, (iii) comparison of neutralizing antibody responses induced by different vaccines, and (iv) correlates of protection.

Guest Editor

Dr. Jianhui Nie

Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing 102629, China

Deadline for manuscript submissions

closed (30 April 2024)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/143299

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI